On diabetic foot, wound healing, amputation prevention, and the merger of consumer tech with medical devices
Three new papers converge on a two-cent idea: the neutrophil percentage-to-albumin ratio (NPAR) measures the balance between inflammatory injury and nutritional reserve — tracking both how bad the diabetic foot is now and how the patient fares over years. Plus a clear-eyed look at why AI-driven precision nutrition isn't here yet, and what it will take.
Windy Cole and colleagues propose a master-protocol basket trial that borrows oncology's tissue-agnostic playbook for hard-to-heal wounds — testing a single mechanism-targeted therapy across diabetic foot and venous leg ulcers under one Bayesian, sham-controlled design. We've spent a decade framing the diabetic foot like cancer; here, the trial architecture grows up to match.
Two diabetic foot data engines published the same day on two continents. STEADY (US) is a 5,000-patient, AI-enabled real-world registry; DARE-DiaFoot (Italy) is a deep, multi-instrumental phenotyping protocol that quietly studies remission. One is the census, the other the core sample. Together with EURODIALE, the U.S. Wound Registry, and the National Diabetes Foot Care Audit, they sketch a blueprint for finally measuring what we manage.
Ninety percent of clinicians know about the Medicare Therapeutic Shoe Benefit and nearly all recommend shoes, yet fewer than one in five eligible patients ever gets them. A new study from Ryan Crews and Carol Kurth shows the bottleneck isn't awareness. It's friction.
Senneville and Lipsky return with a measured rejoinder in Clinical Infectious Diseases (April 2026), arguing that the Lagrand trial shows the absence of evidence of superiority — not definitive equivalence — between ulcer-bed and bone biopsy for guiding antibiotic therapy in diabetic foot osteomyelitis.
A new protocol paper in Sensors describes a chatbot that doses walking like a drug for patients in diabetic foot remission.
A cost-effectiveness analysis of the DIAFOS trial shows that in-shoe plantar pressure-guided custom footwear saves over €8,000 per ulcer prevented — and adherent patients push the probability of cost-effectiveness to 94%. The economic case for prevention just got stronger.
Chronic wounds are biological computers stuck in a boot loop. Sharp debridement is Control-Alt-Delete — the histological reboot that converts a chronic wound back into an acute one. Only then can you run the apps.
A new systematic review finds that roughly one in three adults in remission after a healed diabetic foot ulcer develop a recurrent ulcer within 12 months — a risk comparable to several common cancers. Healing is the beginning of the next chapter, not the end of the story.
FOR IMMEDIATE RELEASE ANTALYA, TURKEY – David G. Armstrong, DPM, MD, PhD, Distinguished Professor of Surgery and Neurological Surgery at the University of Southern California (USC), has been selected to deliver the opening keynote address at the 19th National & 7th International Wound Congress. The event, held at the Titanic Mardan Palace from December 4–7,... Continue Reading →
